Docoh
Loading...

ALNA Allena Pharmaceuticals

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The following proposals were submitted to the stockholders at the 2021 Annual Meeting of Stockholders of Allena Pharmaceuticals, Inc. (the “Company”) held on June 3, 2021 (the “Annual Meeting”):

(i) The election of two Class I directors, as nominated by the Board of Directors of the Company (the “Board”), each to serve a three-year term expiring at the 2024 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal; and

(ii) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.

(iii) The approval of an amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 125,000,000 shares to 200,000,000 shares.

The proposals are described in detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 22, 2021.

The number of shares of common stock entitled to vote at the Annual Meeting was 56,938,327. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 36,487,117. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and all director nominees were elected.

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

(a)Election of Class I Directors.


Director NomineeVotes ForVotes
Withheld
Alexey Margolin, Ph.D19,080,3176,476,905
Mark J. Fitzpatrick24,870,968686,254


There were 10,929,895 broker non-votes regarding the election of directors.

(b)Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.


Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the voting included 35,719,729 votes for, 652,049 votes against and 115,338 votes abstained. There were no broker non-votes regarding this proposal.

(c)Approval of an amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 125,000,000 shares to 200,000,000 shares.


Stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 125,000,000 shares to 200,000,000 shares. The results of the voting included 32,284,987 votes for, 3,717,850 votes against and 484,280 votes abstained. There were no broker non-votes regarding this proposal.